Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Acta Diabetologica

• Publication date

  1995-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00838486PMID 8590785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypersecretion of Truncated Glucagon‐like Peptide‐1 and Gastric Inhibitory Polypeptide in Obese Patients

  1993cited by this paper
• Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

  1991cited by this paper
• Alterations of plasma immunoreactive glucagon-like peptide-1 behavior in non-insulin-dependent diabetics.

  1990cited by this paper
• RADIOIMMUNOASSAY FOR GLUCAGON-LIKE PEPTIDE-1 IN HUMAN PLASMA USING N-TERMINAL AND C-TERMINAL DIRECTED ANTIBODIES: A PHYSIOLOGIC INSULINOTROPIC ROLE OE GLP-1( 7-36 AMIDE)

  1990cited by this paper
• Distribution and molecular forms of glucagon-like peptide in the dog.

  1989cited by this paper
• Gastric Inhibitory Polypeptide (GIP)

  1988cited by this paper
• Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment

  1987cited by this paper
• Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

  1987cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Sulfonylurea stimulates liver fructose-2,6-bisphosphate formation in proportion to its hypoglycemic action.

  1985cited by this paper
• Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues.

  1984cited by this paper
• The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera.

  1984cited by this paper
• Mode of action of hypoglycaemic sulfonylureas in the pancreatic B-cell: coinciding and conflicting views

  1983cited by this paper
• Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment.

  1981cited by this paper
• Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment.

  1981cited by this paper
• Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance

  1979cited by this paper
• Decreased Serum Cholesterol-binding Reserve in Diabetes Mellitus

  1978cited by this paper
• Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels

  1978cited by this paper
• Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus

  1977cited by this paper
• Identification and actions of gastric inhibitory polypeptide.

  1975cited by this paper
• Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man.

  1974cited by this paper
• Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

  1970cited by this paper
• LONG‐TERM STUDIES OF THE SULFONYLUREAS IN TOTALLY DEPANCREATIZED DOGS

  1957cited by this paper

• Understanding the release mechanisms and secretion patterns for glucagon-like peptide-1 using the isolated perfused intestine as a model

  2025cites this paper
• Incretin-based therapy: a new horizon in diabetes management

  2024cites this paper
• The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake

  2021cites this paper
• Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial

  2019cites this paper
• Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes

  2019cites this paper
• The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

  2018cites this paper
• Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes.

  2017cites this paper
• The role of incretins in insulin secretion

  2016cites this paper
• [Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion].

  2016cites this paper
• Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review

  2016cites this paper
• Selective Sodium-Dependent Glucose Transporter 1 inhibitors block glucose absorption and impair 1 glucose-dependent insulinotropic peptide release

  2015cites this paper
• Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.

  2015cites this paper
• Obesity and Diabetes Mellitus

  2014cites this paper
• Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.

  2014cites this paper
• Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

  2013cites this paper
• Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

  2013cites this paper
• Response of low active GLP-1 like substances to test meal in obese Japanese patients with type 2 diabetes mellitus compared with obese controls with normal glucose tolerance

  2012cites this paper
• Normal Response of Active GLP-1 like Substances Level to Test Meal in Non-Obese Type 2 Diabetic Japanese Patients with Complications and Receiving Treatments

  2011influential citation
• GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies

  2011cites this paper
• CHAPTER 31 – Type 2 Diabetes Mellitus

  2011cites this paper
• Normal Response of Active GLP-1 Level like Substances to Test Meal in Non-Obese Type 2 Diabetic Japanese Patients with Complications and Receiving Treatments

  2011cites this paper
• Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

  2010cites this paper
• Bile-induced secretion of glucagon-like peptide-1 4 Pathophysiological implications in type 2 diabetes ? 5 6 7

  2010cites this paper
• Die Bedeutung der Inkretinhormone GIP und GLP-1 für die Pathogenese des Typ-2-Diabetes∗

  2009cites this paper
• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

  2009cites this paper
• No apparent benefit of liquid formula diet in NIDDM.

  2009cites this paper
• A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.

  2009cites this paper
• Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

  2008cites this paper
• Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements.

  2008cites this paper
• Enhanced glucagon‐like peptide‐1 (GLP‐1) response to oral glucose in glucose‐intolerant HIV‐infected patients on antiretroviral therapy

  2005cites this paper
• On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.

  2004cites this paper
• Glucose-sensing in glucagon-like peptide-1-secreting cells.

  2002cites this paper
• Novel insulin/GIP co‐producing cell lines provide unexpected insights into Gut K‐cell function in vivo

  2002cites this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cites this paper
• Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis.

  2000cites this paper
• The glucagon-like peptides.

  1999cites this paper
• Incretin hormone expression in the gut of diabetic mice and rats.

  1997cites this paper
• Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

  1997cites this paper